REGN Stock Up 6% after 5-Day Win Streak
Regeneron Pharmaceuticals (REGN) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 6% return. The company has gained about $3.6 Bil in value over the last 5 days, with its current market capitalization at about $60 Bil. The stock remains 19.7% below its value at the end of 2024. This compares with year-to-date returns of 6.6% for the S&P 500.
Comparing REGN Stock Returns With The S&P 500
The following table summarizes the return for REGN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | REGN | S&P 500 |
|---|---|---|
| 1D | 0.5% | 0.1% |
| 5D (Current Streak) | 6.0% | 0.6% |
| 1M (21D) | 9.0% | 3.8% |
| 3M (63D) | -0.9% | 14.9% |
| YTD 2025 | -19.7% | 6.6% |
| 2024 | -18.9% | 23.3% |
| 2023 | 21.7% | 24.2% |
| 2022 | 14.2% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 41 S&P constituents with 3 days or more of consecutive gains and 36 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 15 | 17 |
| 4D | 21 | 14 |
| 5D | 5 | 2 |
| 6D | 0 | 1 |
| 7D or more | 0 | 2 |
| Total >=3 D | 41 | 36 |
- What’s Next For Fortinet Stock?
- Why Okta’s Slower Growth Is Pressuring The Stock
- Nvidia Stock’s Cheap 25x Multiple The Loudest Warning Yet?
- What Could Rocket Advanced Micro Devices Stock to New Heights
- The Risk Factors to Watch Out For in Tesla Stock
- PayPal Stock: Strong Cash Flow Poised for a Re-Rating?
Key Financials for Regeneron Pharmaceuticals (REGN)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $13.1 Bil | $14.2 Bil |
| Operating Income | $4.0 Bil | $4.0 Bil |
| Net Income | $4.0 Bil | $4.4 Bil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $3.8 Bil | $3.0 Bil |
| Operating Income | $990.2 Mil | $591.7 Mil |
| Net Income | $917.7 Mil | $808.7 Mil |
While REGN stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.